Exhibit 99.2
FORM 51-102F3
MATERIAL CHANGE REPORT
Item1 | Name and Address of Company |
Merus Labs International Inc. (the “Company” or “Merus”)
100 Wellington Street West
Suite 2110, PO Box 151
Toronto, Ontario, M5K 1H1
Item2 | Date of Material Change |
April 30, 2015
Item3 | News Release |
A news release was issued by the Company on April 30, 2015 and distributed through Marketwired and filed on SEDAR.
Item 4 | Summary of Material Change |
The Company completed its bought deal financing announced April 13, 2015 with a syndicate of investment dealers co-led by Clarus Securities Inc., and Cormark Securities Inc. and including Canaccord Genuity Corp., Laurentian Bank Securities Inc., GMP Securities L.P. and TD Securities Inc. Under the financing, Merus issued a total of 19,672,200 common shares (“Shares”) at a price of $3.05 per Share for gross proceeds of $60,000,210.
Item5 | Full Description of Material Change |
5.1 | Full Description of Material Change |
On April 30, 2015, the Company completed its bought deal financing announced April 13, 2015 with a syndicate of investment dealers (the “Underwriters”) co-led by Clarus Securities Inc., and Cormark Securities Inc. and including Canaccord Genuity Corp., Laurentian Bank Securities Inc., GMP Securities L.P. and TD Securities Inc. Under the financing, Merus issued a total of 19,672,200 Shares at a price of $3.05 per Share for gross proceeds of $60,000,210.
The Company has granted to the Underwriters on closing an over-allotment option to purchase an additional 2,950,830 Shares at $3.05 per Share, exercisable in whole or in part, for the period ending May 30, 2015. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the offering will be $69,000,242.
The net proceeds of the offering will be used for working capital and for general corporate purposes, including the funding of prospective future acquisitions.
5.2 | Disclosure for Restructuring Transactions |
Not applicable.
Item 6 | Reliance on subsection 7.1(2) of National Instrument 51-102 |
Not applicable
Item 7 | Omitted Information |
Not applicable
Item 8 | Executive Officer |
Andrew Patient
Chief Financial Officer
Telephone: (416) 593-3725
Item9 | Date of Report |
May 4, 2015